Growing Expertise in Biosimilars

Biosimilars are medicines with very similar structure and function to biologics.

Biosimilars are biological products that are highly similar to reference products despite minor differences in clinically inactive components and have no clinically meaningful differences in safety, purity, and potency. The biologics or biosimilars are produced using a unique cell line and a proprietary process that varies from manufacturer to manufacturer.

Biologics And Biosimilars Lookup

Is there any difference?



The pressure of rising costs of medical treatments for patients across the globe has created a significantly high demand for biosimilars. The biosimilars are expected to serve as a cost-effective alternative to costly biologics, resulting in a much-needed reduction in medical treatment expenditure and improving access to high-quality, life-saving drugs.

Biosimilars: Need of the Hour

Clinical Advantages Market Advantages
Many cancers today are curable at an early stage, like early HER2 - positive breast cancer by Trastuzumab Affordability
Quality of life has been enhanced with MABs, like Adalimumab in RA Increased access
The relapse of the disease has been reduced with Rituximab in NHL Reduces the burden on healthcare spending
Better patient compliance; for example, the use of Erythropoietin/Darbepoetin in CKD has overcome the need for blood transfusions Offers a big market opportunity for biosimilar companies
Wider treatment options for no drug/less option therapy in many diseases Challenges the monopoly of innovator’s pricing models